Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 0.51 Billion | USD 3.43 Billion | 23.60% | 2023 |
FrequentlyAsked Questions
Hemophilia B gene therapy is a one-time novel medical treatment used for treating patients with hemophilia B medical conditions.
The global hemophilia B gene therapy market is expected to grow due to the rising number of patients suffering from the medical condition.
According to study, the global hemophilia B gene therapy market size was worth around USD 0.51 billion in 2023 and is predicted to grow to around USD 3.43 billion by 2032.
The CAGR value of the hemophilia B gene therapy market is expected to be around 23.60% during 2024-2032.
The global hemophilia B gene therapy market is expected to be dominated by North America in the coming years.
The global hemophilia B gene therapy market is led by players like Freeline Therapeutics, CSL Behring, Alnylam Pharmaceuticals, Dimension Therapeutics, Bayer AG, Pfizer Inc., Sangamo Therapeutics, Roche Holding AG, Spark Therapeutics, Genethon, uniQure N.V., REGENXBIO Inc., BioMarin Pharmaceutical Inc., Novo Nordisk A/S and Shire plc (now part of Takeda Pharmaceutical Company).
The report explores crucial aspects of the hemophilia B gene therapy market, including a detailed discussion of existing growth factors and restraints while also browsing future growth opportunities and challenges that impact the market.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed